MILLENNIUM PHARMACEUTICALS, INC.;MASSACHUSETTS GENERAL HOSPITAL; INC.;MILLENNIUM PHARMACEUTICALS
发明人:
BENES, CYRIL H.,BLAKEMORE, STEPHEN J.,BLANK, JONATHAN L.,LIGHTCAP, ERIC S.,MULLIGAN, GEORGE J.,SCHU, MATTHEW C.,SMITH, PETER G.,SETTLEMAN, JEFFREY E.
申请号：
CA2853822
公开号：
CA2853822A1
申请日:
2012.10.26
申请国别(地区):
CA
年份:
2013
代理人:
摘要：
Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
